{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T06:15:26Z","timestamp":1778652926097,"version":"3.51.4"},"reference-count":18,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Lymph node metastasis (LNM) is a major prognostic determinant in early-stage cervical squamous cell carcinoma (SCC); however, conventional preoperative imaging has demonstrated sensitivities below 60% for sub-centimeter metastases, resulting in treatment misallocation for approximately 20\u201330% of patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>This study aimed to develop and validate a minimal gene expression signature that can be performed on routine biopsy specimens to predict preoperative LNM in cervical SCC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective biomarker discovery and validation study had a two-phase design. In the discovery phase, we analyzed transcriptomic data from 116 The Cancer Genome Atlas (TCGA) cervical SCC samples and identified differentially expressed genes (DEGs) using Benjamini\u2013Hochberg (BH) false discovery rate correction (FDR\u202f&amp;lt;\u202f0.10). Then, we refined them using the least absolute shrinkage and selection operator (LASSO) regression analysis and multivariate logistic regression analysis. The locked signature was independently validated in a prospectively collected cohort of 202 patients (101 LNM-positive patients and 101 LNM-negative patients) from the Fudan University Shanghai Cancer Center using quantitative reverse transcription\u2013polymerase chain reaction (qRT-PCR), with histopathological lymphadenectomy confirmation as the reference standard. Performance was assessed based on area under the curve (AUC), sensitivity, specificity, predictive values, and bootstrap internal validation. Decision curve analysis and a combined molecular-clinical model were also evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of the 231 DE genes, a three-gene signature (LOC494141, GLOD5, and GML) was identified by sequential filtering. In the independent validation cohort, the signature achieved an AUC of 0.745 (95% CI: 0.676\u20130.814), with a sensitivity of 62.38%, a specificity of 64.36%, a positive predictive value of 63.64%, and a negative predictive value of 63.11%. Bootstrap validation confirmed model robustness (optimism-corrected AUC: 0.722; calibration slope: 0.913; Hosmer\u2013Lemeshow\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.387). A combined model integrating the signature with tumor size and lymphovascular space invasion achieved an AUC of 0.789 (95% CI: 0.724\u20130.854), with a significant incremental value [net reclassification improvement (NRI)\u202f=\u202f0.42,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.001; integrated discrimination improvement (IDI)\u202f=\u202f0.065,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&amp;lt;\u202f0.001]. Decision curve analysis demonstrated net clinical benefit across threshold probabilities of 20\u201370%. At a 20% population prevalence, the adjusted negative predictive value reached 87.3%.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This three-gene expression signature provides clinically informative preoperative risk stratification for LNM in cervical SCC. Intended as a complementary tool within integrated clinical assessment frameworks rather than a standalone diagnostic tool, this affordable qRT-PCR-based assay holds particular promise for resource-limited settings, pending prospective multicenter validation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1797844","type":"journal-article","created":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T05:57:04Z","timestamp":1778651824000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["A three-gene expression signature predicts lymph node metastasis in cervical squamous cell carcinoma: development and validation using TCGA and clinical cohorts"],"prefix":"10.3389","volume":"13","author":[{"given":"Yachen","family":"Duan","sequence":"first","affiliation":[{"name":"Department of Gynecological Oncology, Fudan University Shanghai Cancer Center","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiajia","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Gynecological Oncology, Fudan University Shanghai Cancer Center","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaohua","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Gynecological Oncology, Fudan University Shanghai Cancer Center","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,13]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"200238","DOI":"10.1016\/j.tvr.2022.200238","article-title":"Cervical cancer therapies: current challenges and future perspectives","volume":"13","author":"Burmeister","year":"2022","journal-title":"Tumour Virus Res"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3389\/fonc.2025.1654368","article-title":"Rare widespread dissemination of cervical high-grade squamous intraepithelial lesion with microinvasive squamous cell carcinoma: a case report","volume":"15","author":"Liu","year":"2025","journal-title":"Front Oncol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1007\/s10147-024-02605-0","article-title":"Long-term outcomes of sentinel lymph node navigation surgery for early-stage cervical cancer","volume":"29","author":"Togami","year":"2024","journal-title":"Int J Clin Oncol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3389\/fonc.2022.809159","article-title":"Risk factor assessment of lymph node metastasis in patients with FIGO stage IB1 cervical Cancer. Frontiers","volume":"12","author":"Xu","year":"2022","journal-title":"Oncology"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1102\/1470-7330.2009.0017","article-title":"Nodal staging","volume":"9","author":"Ganeshalingam","year":"2009","journal-title":"Cancer Imaging"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/s12951-024-02408-5","article-title":"Revolutionizing lymph node metastasis imaging: the role of drug delivery systems and future perspectives","volume":"22","author":"Cai","year":"2024","journal-title":"J Nanobiotechnol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.2967\/jnumed.108.055780","article-title":"18F-FDG PET\/CT for image-guided and intensity-modulated radiotherapy","volume":"50","author":"Ford","year":"2009","journal-title":"J Nucl Med"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/1756-9966-27-52","article-title":"Positron emission tomography (PET) radiotracers in oncology \u2013 utility of 18F-Fluoro-deoxy-glucose (FDG)-PET in the management of patients with non-small-cell lung cancer (NSCLC)","volume":"27","author":"Miele","year":"2008","journal-title":"J Exp Clin Cancer Res"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1503\/cmaj.071124","article-title":"Diagnostic accuracy of tests for lymph node status in primary cervical cancer: a systematic review and meta-analysis","volume":"178","author":"Selman","year":"2008","journal-title":"Can Med Assoc J"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"189106","DOI":"10.1016\/j.bbcan.2024.189106","article-title":"Emerging biomarkers and molecular targets for precision medicine in cervical cancer. Biochimica et Biophysica Acta (BBA) - reviews on","volume":"1879","author":"Garg","year":"2024","journal-title":"Cancer"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"g7594","DOI":"10.1136\/bmj.g7594","article-title":"Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement","volume":"350","author":"Collins","year":"2015","journal-title":"BMJ"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"e012799","DOI":"10.1136\/bmjopen-2016-012799","article-title":"STARD 2015 guidelines for reporting diagnostic accuracy studies: explanation and elaboration","volume":"6","author":"Cohen","year":"2016","journal-title":"BMJ Open"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.3390\/biology11121752","article-title":"A systems biology and LASSO-based approach to decipher the transcriptome-Interactome signature for predicting non-small cell lung Cancer","volume":"11","author":"Ahmed","year":"2022","journal-title":"Biology (Basel)"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1186\/s12967-025-06327-3","article-title":"A gene-based predictive model for lymph node metastasis in cervical cancer: superior performance over imaging techniques","volume":"23","author":"Xu","year":"2025","journal-title":"J Transl Med"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1136\/ijgc-00009577-200205000-00010","article-title":"P53 expression as a predictor of recurrence in cervical squamous cell carcinoma","volume":"12","author":"Brenna","year":"2002","journal-title":"Int J Gynecol Cancer"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"101728","DOI":"10.1016\/j.gendis.2025.101728","article-title":"Defective biological networks associated with pseudogene-derived lncRNAs in cancer drug resistance: promising prospects for their clinical targets in cancer therapy","volume":"13","author":"Aghajani Mir","year":"2026","journal-title":"Genes Dis"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3389\/fonc.2020.537311","article-title":"GPI-AP: Unraveling a new class of malignancy mediators and potential immunotherapy targets","volume":"10","author":"Hussein","year":"2020","journal-title":"Front Oncol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1797844\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T05:57:06Z","timestamp":1778651826000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1797844\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,13]]},"references-count":18,"alternative-id":["10.3389\/fmed.2026.1797844"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1797844","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,13]]},"article-number":"1797844"}}